ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm

robot
Abstract generation in progress

The Rosen Law Firm has filed a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) on behalf of investors who purchased securities between November 3, 2023, and March 16, 2026. The lawsuit alleges that Aldeyra made false and misleading statements regarding inconsistent clinical trial results for its reproxalap drug candidate. Investors who purchased shares during this period have until May 29, 2026, to move the Court to serve as lead plaintiff.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin